AGN - Actavis Ltd
Form S-4/A Period: JAN.26.15 Date Filed: JAN.26.15
Transcript Split
  
  
     
Move to First Section Move to Last Section
INDEX
ItemizedPage-by-Page
  Form S-4/A (Entire Filing)

Filing Body

Page 1: As filed with the Securities and Exchange Commission on January 26, 2015

Page 2: Information contained herein is subject to completion or amendment. A registration statement relatin

Page 3: Information contained herein is subject to completion or amendment. A registration statement relatin

Page 4: ADDITIONAL INFORMATION

Page 5: ACTAVIS PLC

Page 6: Please note that if shareholders plan to attend the Actavis EGM in person, they will need to registe

Page 7: N/A

Page 8: ALLERGAN, INC.

Page 9: The Allergan board of directors has unanimously approved and declared advisable the Merger Agreement

Page 10: TABLE OF CONTENTS

Page 11: N/A

Page 12: N/A

Page 13: N/A

Page 14: QUESTIONS AND ANSWERS ABOUT THE TRANSACTIONS AND THE ACTAVIS EXTRAORDINARY GENERAL MEETING AND THE A

Page 15: Appraisal Rights

Page 16: Stock Options

Page 17: Restricted Stock Units

Page 18: The Actavis Share Issuance Proposal

Page 19: Risk Factors

Page 20: The Merger-Related Named Executive Officer Compensation Proposal

Page 21: Actavis

Page 22: Actavis

Page 23: Actavis

Page 24: Actavis

Page 25: Allergan

Page 26: Appraisal Rights

Page 27: Where You Can Find More Information

Page 28: SUMMARY

Page 29: Restricted Stock Held by Continuing Employee

Page 30: The Merger Agreement Treatment of Allergan Stock Options and Other Allergan Equity-Based Awards

Page 31: Recommendation of the Allergan Board of Directors and Allergan s Reasons for the Merger (page 83)

Page 32: The Merger Opinion of Actavis Financial Advisor

Page 33: The full text of the written opinion of Goldman Sachs, dated November 16, 2014, which sets forth ass

Page 34: Interests of Allergan s Directors and Executive Officers in the Transactions (page 122)

Page 35: Board of Directors and Management after the Transactions (page 122)

Page 36: Other Regulatory Approvals

Page 37: The Merger Agreement Covenants and Agreements

Page 38: Change of Recommendation (page 151)

Page 39: Actavis Change of Recommendation

Page 40: The Merger Agreement Conditions to the Completion of the Merger

Page 41: Termination Fees Payable by Actavis

Page 42: Termination Fees Payable by Allergan

Page 43: Bridge Credit Agreement

Page 44: Accounting Treatment of the Transactions (page 132)

Page 45: Certain Tax Consequences of the Merger U.S. Federal Income Tax Considerations

Page 46: Merger Sub

Page 47: RISK FACTORS

Page 48: Actavis does not intend to pay dividends in the foreseeable future, and current Allergan stockholder

Page 49: The Merger Agreement Termination of the Merger Agreement; Termination Fees; Expense Reimbursement

Page 50: The Merger Agreement Termination of the Merger Agreement; Termination Fees; Expense Reimbursement

Page 51: Actavis ordinary shares to be received by Allergan stockholders as a result of the Merger will have

Page 52: Actavis ordinary shares received by means of a gift or inheritance could be subject to Irish capital

Page 53: Actavis and Allergan will incur direct and indirect costs as a result of the Merger.

Page 54: Actavis expects that, for a period of time following the consummation of the Merger, Actavis will ha

Page 55: Actavis and Allergan s actual financial positions and results of operations may differ materially fr

Page 56: The Internal Revenue Service may not agree that Actavis is a foreign corporation for U.S. federal ta

Page 57: Actavis status as a foreign corporation for U.S. federal tax purposes could be affected by a change

Page 58: Legislative or other governmental action relating to the denial of U.S. federal or state governmenta

Page 59: Certain Tax Consequences of the Merger Irish Tax Considerations Withholding Tax on Dividends (DWT)

Page 60: CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

Page 61: SELECTED HISTORICAL FINANCIAL DATA OF ACTAVIS

Page 62: N/A

Page 63: N/A

Page 64: SELECTED HISTORICAL FINANCIAL DATA OF ALLERGAN

Page 65: SELECTED UNAUDITED PRO FORMA FINANCIAL DATA

Page 66: COMPARATIVE HISTORICAL AND UNAUDITED PRO FORMA PER SHARE FINANCIAL DATA

Page 67: N/A

Page 68: THE ACTAVIS EXTRAORDINARY GENERAL MEETING

Page 69: Actavis Record Date and Quorum

Page 70: EVERY ACTAVIS SHAREHOLDER S VOTE IS IMPORTANT. ACCORDINGLY, EACH ACTAVIS SHAREHOLDER SHOULD VOTE VIA

Page 71: Solicitation of Proxies

Page 72: ACTAVIS PROPOSALS

Page 73: THE ALLERGAN SPECIAL MEETING

Page 74: Required Vote

Page 75: FOR

Page 76: Revocability of Proxies and Changes to an Allergan Stockholder s Vote

Page 77: Assistance

Page 78: ALLERGAN PROPOSALS

Page 79: RESOLVED, that the compensation that may be paid or become payable to Allergan s named executive off

Page 80: INFORMATION ABOUT THE COMPANIES

Page 81: THE MERGER

Page 82: N/A

Page 83: N/A

Page 84: N/A

Page 85: N/A

Page 86: N/A

Page 87: N/A

Page 88: N/A

Page 89: N/A

Page 90: Opinion of Actavis Financial Advisor

Page 91: Recommendation of the Actavis Board of Directors and Actavis Reasons for the Merger

Page 92: Synergies

Page 93: Governance

Page 94: N/A

Page 95: N/A

Page 96: Cautionary Statement Regarding Forward-Looking Statements

Page 97: N/A

Page 98: N/A

Page 99: N/A

Page 100: Opinion of Actavis Financial Advisor

Page 101: Actavis Unaudited Prospective Financial Information

Page 102: Allergan Unaudited Prospective Financial Information

Page 103: Public Trading Multiples Analysis

Page 104: Actavis Unaudited

Page 105: Allergan Unaudited Prospective Financial Information

Page 106: Discounted Cash Flow Analysis With Synergies

Page 107: Miscellaneous

Page 108: Opinions of Allergan s Financial Advisors

Page 109: its opinion to the Allergan board of directors for the benefit and use of the Allergan board of dire

Page 110: N/A

Page 111: The financial analyses summarized below include information presented in tabular format. In order to

Page 112: Present Value of Future Stock Price Analysis

Page 113: Selected Publicly Trading Companies Analyses

Page 114: Discounted Cash Flow Analyses

Page 115: Present Value of Future Stock Price Analyses

Page 116: Actavis Pro Forma

Page 117: Other Factors

Page 118: Miscellaneous

Page 119: N/A

Page 120: Goldman, Sachs Co.

Page 121: Implied Premia and Multiples Analyses

Page 122: N/A

Page 123: Selected Companies Analyses

Page 124: N/A

Page 125: Selected Precedent Transactions Analyses

Page 126: Illustrative Present Value of Future Share Price Analyses

Page 127: Illustrative Discounted Cash Flow Analyses

Page 128: General

Page 129: Actavis Unaudited Prospective Financial Information

Page 130: Risk Factors

Page 131: Risk Factors

Page 132: Allergan Unaudited Prospective Financial Information

Page 133: N/A

Page 134: Risk Factors

Page 135: Board of Directors and Management after the Transactions

Page 136: Restricted Stock Held by Continuing Employees

Page 137: Quantification of Payments and Benefits to Allergan s Named Executive Officers

Page 138: Quantification of Payments and Benefits to Allergan s Named Executive Officers

Page 139: Retention Bonus Pool

Page 140: Change in Control Policy

Page 141: Regulatory Approvals Required for the Merger

Page 142: Stock Exchange Listing

Page 143: Bridge Credit Agreement

Page 144: Transaction-Related Costs

Page 145: Accounting Treatment of the Transactions

Page 146: THE MERGER AGREEMENT

Page 147: Consideration to Allergan Stockholders

Page 148: Appraisal Rights

Page 149: Treatment of Allergan Stock Options and Other Allergan Equity-Based Awards

Page 150: Post-Signing Equity Grants

Page 151: N/A

Page 152: N/A

Page 153: No Survival of Representations and Warranties

Page 154: Covenants and Agreements

Page 155: N/A

Page 156: N/A

Page 157: N/A

Page 158: Employee Matters

Page 159: Litigation Relating to the Transaction

Page 160: Irish Stamp Duty

Page 161: Reasonable Best Efforts; Regulatory Filings and Other Actions

Page 162: No Solicitation; Third-Party Acquisition Proposals

Page 163: Definition of Competing Acquisition Proposal

Page 164: Change of Recommendation

Page 165: Actavis Change of Recommendation

Page 166: Certain Additional Covenants

Page 167: N/A

Page 168: Termination of the Merger Agreement; Termination Fees; Expense Reimbursement

Page 169: Termination Fees

Page 170: Expense Reimbursement Payable by Allergan

Page 171: Amendment and Waiver

Page 172: CERTAIN TAX CONSEQUENCES OF THE MERGER

Page 173: U.S. Federal Income Tax Consequences of the Merger

Page 174: N/A

Page 175: Tax Consequences to U.S. Holders

Page 176: Ownership and Disposition of Actavis Ordinary Shares

Page 177: N/A

Page 178: Sale, Exchange or Other Taxable Disposition

Page 179: Information Reporting and Backup Withholding

Page 180: Irish Tax Considerations

Page 181: Stamp Duty

Page 182: Withholding Tax on Dividends (DWT)

Page 183: Shares Held by U.S. Resident Shareholders

Page 184: Shares Held by Residents of Ireland

Page 185: Capital Acquisitions Tax (CAT)

Page 186: UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION

Page 187: N/A

Page 188: Actavis plc

Page 189: Actavis plc

Page 190: Actavis plc

Page 191: Actavis plc

Page 192: Actavis plc

Page 193: Actavis plc

Page 194: 1. Description of Transactions

Page 195: 3. Accounting Policies

Page 196: Reclassifications and classification in the unaudited pro forma combined statement of operations for

Page 197: 5. Historical Forest

Page 198: Reclassifications and classifications in the unaudited pro forma combined statement of operations fo

Page 199: Reclassifications and classifications in the unaudited pro forma combined statement of operations fo

Page 200: 6. Historical Aptalis

Page 201: Reclassifications and classifications in the unaudited pro forma combined statement of operations fo

Page 202: 8. Unaudited Pro Forma Combined Balance Sheet Adjustments

Page 203: N/A

Page 204: N/A

Page 205: 9. Unaudited Pro Forma Combined Statement of Operations Adjustments

Page 206: Adjustments Related to the Forest Transaction

Page 207: N/A

Page 208: Adjustments Related to the Aptalis Transaction

Page 209: Adjustments Related to the Warner Chilcott Transaction

Page 210: 10. Earnings per Share

Page 211: COMPARATIVE PER SHARE MARKET PRICE INFORMATION

Page 212: N/A

Page 213: COMPARISON OF THE RIGHTS OF HOLDERS OF ACTAVIS ORDINARY SHARES AND ALLERGAN COMMON STOCK

Page 214: N/A

Page 215: N/A

Page 216: N/A

Page 217: N/A

Page 218: N/A

Page 219: N/A

Page 220: N/A

Page 221: N/A

Page 222: N/A

Page 223: N/A

Page 224: N/A

Page 225: N/A

Page 226: N/A

Page 227: N/A

Page 228: N/A

Page 229: N/A

Page 230: N/A

Page 231: N/A

Page 232: N/A

Page 233: N/A

Page 234: N/A

Page 235: N/A

Page 236: N/A

Page 237: N/A

Page 238: N/A

Page 239: N/A

Page 240: N/A

Page 241: N/A

Page 242: N/A

Page 243: N/A

Page 244: N/A

Page 245: N/A

Page 246: N/A

Page 247: N/A

Page 248: DESCRIPTION OF ACTAVIS ORDINARY SHARES

Page 249: Issued Share Capital

Page 250: Share Repurchases, Redemptions and Conversions

Page 251: Purchases by Subsidiaries of Actavis

Page 252: Annual Meetings of Shareholders

Page 253: Quorum for General Meetings

Page 254: Action by Written Consent

Page 255: Appraisal Rights

Page 256: Anti-Takeover Provisions

Page 257: Mandatory Bid

Page 258: Insider Dealing

Page 259: Appointment of Directors

Page 260: Duration; Dissolution; Rights upon Liquidation

Page 261: N/A

Page 262: SHARE OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT/DIRECTORS

Page 263: N/A

Page 264: N/A

Page 265: STOCK OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT/DIRECTORS (ALLERGAN)

Page 266: Stockholders Holding 5% or More

Page 267: EXPERTS

Page 268: ENFORCEABILITY OF CIVIL LIABILITIES

Page 269: ALLERGAN ANNUAL MEETING STOCKHOLDER PROPOSALS

Page 270: APPRAISAL RIGHTS

Page 271: Filing Written Demand

Page 272: Notice by the Surviving Corporation

Page 273: Filing a Petition for Appraisal

Page 274: N/A

Page 275: HOUSEHOLDING OF PROXY MATERIALS

Page 276: N/A

Page 277: N/A

Page 278: Annex A

Page 279: TABLE OF CONTENTS

Page 280: TABLE OF CONTENTS

Page 281: TABLE OF CONTENTS

Page 282: AGREEMENT AND PLAN OF MERGER

Page 283: AGREEMENT

Page 284: Governing Documents

Page 285: Cancellation of Company Common Stock

Page 286: Procedures for Surrender

Page 287: Section 2.2

Page 288: Lost, Stolen or Destroyed Certificates

Page 289: Treatment of Company Equity Awards

Page 290: Section 2.4(e),

Page 291: Option Consideration

Page 292: multiplied by

Page 293: Capitalization

Page 294: Corporate Authority Relative to this Agreement; No Violation

Page 295: Section 3.3(b)

Page 296: GAAP

Page 297: Compliance with Laws; Permits

Page 298: Employee Benefit Plans

Page 299: Section 3.9(g)

Page 300: Absence of Certain Changes or Events

Page 301: Section 3.12

Page 302: et seq

Page 303: EMA

Page 304: Section 3.13

Page 305: Tax Matters

Page 306: Intellectual Property

Page 307: Company Permitted Lien

Page 308: Required Vote; State Takeover Statutes

Page 309: N/A

Page 310: Section 3.20(a)

Page 311: Insurance

Page 312: Sanctions

Page 313: ARTICLE IV.

Page 314: Parent Capitalization Date

Page 315: Section 5.4

Page 316: Reports and Financial Statements

Page 317: Section 4.6

Page 318: Employee Benefit Plans

Page 319: N/A

Page 320: Absence of Certain Changes or Events

Page 321: Section 4.12

Page 322: Parent Healthcare and Data Protection Laws

Page 323: N/A

Page 324: Section 4.13

Page 325: Labor Matters

Page 326: Intellectual Property

Page 327: Parent Leased Real Property

Page 328: Section 4.20(a)

Page 329: N/A

Page 330: Section 4.20(a)

Page 331: Financing

Page 332: FCPA and Anti-Corruption

Page 333: No Merger Sub Activity

Page 334: N/A

Page 335: N/A

Page 336: provided

Page 337: Section 5.1(ii)

Page 338: N/A

Page 339: Solicitation by the Company

Page 340: Section 5.3

Page 341: Section 5.3

Page 342: provided

Page 343: Section 5.4

Page 344: N/A

Page 345: Section 5.5(b)

Page 346: Section 5.4

Page 347: Consultation as to Certain Tax Matters

Page 348: provided

Page 349: Article VII

Page 350: Section 6.2(b)

Page 351: provided

Page 352: provided

Page 353: Section 6.4

Page 354: Company 401(k) Plans

Page 355: Section 6.7

Page 356: Section 6.9

Page 357: provided

Page 358: Section 6.13

Page 359: Replacement Financing

Page 360: Section 6.15

Page 361: Listing

Page 362: Section 4.1

Page 363: Section 8.1(d)

Page 364: Effect of Termination

Page 365: Section 8.1(g)

Page 366: Section 8.2

Page 367: Section 9.9(b)

Page 368: N/A

Page 369: Certain Definitions

Page 370: Company Bylaws

Page 371: Section 5.1

Page 372: Company Product

Page 373: Confidentiality Agreement

Page 374: Environmental Law

Page 375: Financing

Page 376: HSR Act

Page 377: Key Product

Page 378: Notified Body

Page 379: N/A

Page 380: Parent Product

Page 381: Requisite Jurisdictions

Page 382: Superior Proposal Acquisition Agreement

Page 383: Terms Defined Elsewhere

Page 384: N/A

Page 385: N/A

Page 386: Interpretation

Page 387: Counterparts

Page 388: Severability

Page 389: Section 9.11(b)

Page 390: SECTION 9.12

Page 391: Section 9.14

Page 392: N/A

Page 393: Annex B

Page 394: N/A

Page 395: N/A

Page 396: Annex C

Page 397: N/A

Page 398: N/A

Page 399: N/A

Page 400: Annex D

Page 401: N/A

Page 402: N/A

Page 403: Annex E

Page 404: N/A

Page 405: N/A

Page 406: N/A

Page 407: Annex F

Page 408: PART II

Page 409: N/A

Page 410: N/A

Page 411: N/A

Page 412: SIGNATURES

Page 413: Signature

Exhibits

   CURRENT PAGE
    Download Current Page as a Word Document  Download Current Page as a PDF Document    Download Excel File of Financials